李良成博士、副教授 博士生导师
个人简历：
2001年毕业于中国医学科学院、中国协和医科大学药物研究所，获理学博士学位。2002年起先后在美国新泽西医科和牙科大学，美国伊利诺伊大学芝加哥分校从事博士后及访问学者研究，现为厦门大学药学院副教授。长期以来从事肿瘤和糖尿病的发病机理及药物开发研究。已获得4项发明专利授权，其中包括一项美国专利授权（Pub. NO. US 20110117627 A1)。并有多篇文章在Cancer Research，Diabetes, The Journal of Biological Chemistry，J. Immunology，PlosOne, Thyroid, Acta Pharmaceutica Sinica，Acta Pharmacol Sin 等专业杂志上发表.目前是《天然产物研究与开发》编委，同时也是Cell & Biosciences， Plos One, Toxicology and Applied Pharmacology等多家专业杂志的审稿人。
教育背景：
1998-2001中国医学科学院、中国协和医科大学药物研究所,药理学 获理学博士学位
1993-1996中国科学院西北高原生物研究所,神经生物学 获理学硕士学位
1987-1991中国农业大学生物学院,动物生理与生物化学 获理学学士学位
主要研究方向：
1.从事生化和分子药理学研究；
2.研究肿瘤和糖尿病发病机理及药物作用新靶点；
3.利用基因的可变剪切进行肿瘤早筛生物标志物发现及早筛试剂盒开发；
4.开发胰岛再生诱导剂，为治愈2型糖尿病提供理论基础和先导化合物。
代表性论文（节选）：
1. Hu, XM., Wang,CC, Xiao, Y., Liu,Y. Huang,H., Jiang,P., Wang,YK., Lin,YJ., Li, L-C. *, Qi, ZQ. *, Non-Clinical Safety Evaluation of Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells in Cynomolgus Monkeys. International Journal of Nanomedicine,2024,19, 4923–4939
2. Huang, FR. Lai, JS., Qian, LX, Hong, W., Li, L-C*. Differentiation of Uc-MSCs into insulin secreting islet-like clusters by trypsin through TGF-beta signaling pathway. Differentiation.2024,135(100744).
3. Li, Y., Li, ZW., Hong, W.*, Li, L-C*. Pharmacogenomics of Insulin Secretagogues in Pharmacodynamics, Pharmacokinetics and Adverse Reactions. Austin J Pharmacol Ther.2021, 9(6):1152-58.
4. Li, L., Guo,QY., Liu,YX., Wang,XM. ∗, Li, L-C∗, Ren L.∗ Targeted combination therapy for glioblastoma by co-delivery of doxorubicin, YAP-siRNA and gold nanorods. J. Mater. Sci. Technol.63 (2021) 81–90.
5. Zhang, SM., Huang, FR., Tian, WJ., Lai, JF., Qian, LX., Hong, WJ. *, Chen, HF. *, Li, L-C*. Andrographolide promotes PANC-1 Differentiation into Insulin-producing Cells. Biochemical Pharmacology.2020, 174:113785.
6. Zhou,YX., Liu, ZY., Zhang,SM., Zhuang,RJ., Liu,HY., Liu, XQ., Qiu, X., Zhang,M., Zheng, YP., Li, L-C., Wanjin Hong,W*., and Wang., TL*. RILP Restricts Insulin Secretion Through Mediating Lysosomal Degradation of Proinsulin. Diabetes 2020 Jan;69(1):67-82.
7. 张圣梅, 黄飞榕, 齐忠权, 李良成* .糖尿病细胞治疗供体细胞来源及其研究进展.《实用器官移植电子杂志》2018, 6(2):139-145.
8. Wang, T1, Li, L-C, Hong, W., SNARE proteins in membrane trafficking.Traffic. 2017 Dec;18(12):767-775.
9. Le, KQ#., Prabhakar, BS., Hong,W., Li, L-C*. Alternative Splicing asaBiomarker and Potential Target for Drug Discovery.Acta Pharmacologica Sinica. 2015, 36 (10):1212-1218.
10. Thiruppathi, M#, Sheng, JR, Li, L-C, Prabhakar, BS, Meriggioli, MN*. Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis. J Autoimmun. 2014 Jan 2. pii: S0896-8411(13)00161-3.
11. Li, L-C#., Carr, R., Haddad, CS., Wang, Y., Lee, DY.,Qian, L-X., Qin, JZ., Oberholzer, J., Prabhakar, BS*., IG20/MADD Plays a Critical Role in Glucose-Induced Insulin Secretion.Diabetes. 2014 May;63(5):1612-23.
12. Jayarama, S#., Li, L-C#., Ganesh, L., Mardi, D., Kanteti, P., Hay, N., Li, PF., Prabhakar, BS*. MADD is a downstream target of PTEN in triggering apoptosis.J. Cell. Biochem. 2014, 115 (2): 261-70. (# co-first author).
13. Li, L-C#, Shankara Jayarama#, Tania Pilli#, Lixia Qian, Lakshmy Ganesh, Furio Pacini, Bellur S. Prabhakar*, Abrogation of the IG20 gene expression renders TRAIL resistant thyroid cancer cells susceptible to TRAIL treatment. Thyroid, 2012, 9.
14. Turner, A#., Li, L-C#., Pilli, T., Qian, L-X., Wiley, EL., Prabhakar, BS*., MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.PlosOne, 2013 ,8(2): e56817. (# co-first author).
15. Li L-C#. Jayarama S., Ganesh L., Qian LX., Rotmensch J., Prabhakar BS*., Knockdown of MADD and c-FLIP overcome resistance to TRAIL-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol. 2011 Oct;205(4):362.e12-25.
16. Kurada, BRVVSNK#. Li, LC#., Subramanian M., Mulherkar, N.,Prasad KV., Prabhakar, BS*. MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon TNF treatment. J. Bio. Chem.2009, 15; 284 (20) :13533-41.
17. Sheng JR, Li, LC, Prabhakar BS, Meriggioli MN*. Acetylcholine receptor-alpha subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis?Muscle Nerve. 2009, 40(2):279-86.
18. Li, LC#., Sheng, JR, Mulherkar, N., Prabhakar, BS., Meriggio MN Regulation of apoptosis and caspase-8 expression in nueroblastoma cells by isoform of the IG20 gene.Cancer Res.2008,15;68(18):7352-61.
19. Sheng JR, Li, LC, Ganesh BB, Prabhakar BS, Meriggioli MN. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis.Clin Immunol.2008 Aug;128(2):172-80. Epub 2008 May 27.
20. Meriggioli MN, Sheng JR, Li, LC, Prabhakar BS*. Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis.Ann N Y Acad Sci. 2008;1132:276-82.
21. Sheng, JR, Li, LC and Meriggioli, MN* et al. Suppression of Experimental Autoimmune Myasthenia Gravis by Granulocyte-Macrophage Colony-Stimulating Factor Is Associated with an Expansion of FoxP3+ Regulatory T Cells. J. Immuno.2006, 177(8):5296-306.
22. Li, LC#., Hou,Q., Guo, Y., and Cheng, GF*. Inhibitory effect and mechanism of action of Saggenon C on human polymorphonuclear leukocyte adhesion to human synovial cell.Acta Pharmacol Sin. 2002 ,23(2):138-142.
23. Li, LC#., Shen, F., Hou,Q., and Cheng, GF*. Inhibitory effect of meloxicam on human polymorphonuclear leukocyte adhesion to human synovial cell. Acta Pharmaceutica Sinica, 2002, 37:103-107.
联系方式：
地址：福建省厦门市翔安区翔安南路4221-115，厦门大学药学,355室
邮编：361102
电话：0592-2881126
E-mail：lchli2013 at@ xmu.edu.cn
